| Status: Partially superseded | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA926: Baricitinib for treating severe alopecia areata |
|
Medicine details |
|
| Medicine name | baricitinib (Olumiant®) |
| Formulation | 2 mg, 4 mg film-coated tablet |
| Reference number | 4867 |
| Indication | Treatment of severe alopecia areata in adult patients |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Anaesthesia |
| Assessment type | Directed |
| Status | Partially superseded |
| Date of issue | 29/06/2022 |
| NICE guidance | |